Medicure (TSXV: MPH), a Canadian specialty pharma focused on the development and commercialization of therapeutics for the US hospital market, has exercised an option to snap up additional interests in Apicore, the New Jersey-based API developer and manufacturer.
The option exercise allows for the acquisition of all of the shares held by Apicore’s founding shareholders - representing approximately 32% of the fully diluted ownership - for $24.5 million.
This acquisition brings Medicure's ownership in Apicore to approximately 98%, or 94% on a fully-diluted basis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze